1,602 results on '"Hecht, J."'
Search Results
2. Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities
3. Next-Generation Approaches to Immuno-Oncology in GI Cancers.
4. Fecal and Tissue Microbiota Are Associated with Tumor T-Cell Infiltration and Mesenteric Lymph Node Involvement in Colorectal Cancer.
5. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
6. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips
7. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)
8. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens
9. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
10. Open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-175 in human leukocyte antigen-a*02:01-positive adult subjects with unresectable, advanced and/or metastatic solid tumors that are positive for the TP53 R175H mutation.
11. Improving ethnic and racial diversity in biomarker-driven clinical trials: A proof of concept with the BASECAMP-1 master prescreening study of patients with high-risk solid tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH).
12. Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities.
13. Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented
14. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
15. Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).
16. Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study.
17. BOLD-100-001 (TRIO039): A phase 2 study of BOLD-100 in combination with FOLFOX in patients with advanced mCRC previously treated with FOLFOX/CAPOX—Efficacy and safety analysis.
18. A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second‐Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma
19. A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma
20. Familial Duodenal Somatostatinomatosis Not Associated With a Known Genetic Syndrome
21. 634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)
22. 636 BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials
23. 747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors
24. Impact of Storm‐Time Enhanced O2 Absorption on Disk Viewing N2 LBH Spectra: TIMED GUVI Observations
25. A “Boreing” Night of Observations of the Upper Mesosphere and Lower Thermosphere Over the Andes Lidar Observatory
26. Atmospheric Gravity Wave and Instability Observations From the International Space Station Using the Near InfraRed Airglow Camera (NIRAC)
27. 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study.
28. Diagnostic fetoscopy: important resource of prenatal assessment
29. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
30. Abstract CT149: BOLD-100-001 (TRIO039): a phase 1b/2a dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced colorectal cancer: interim efficacy, safety and tolerability analysis
31. Data from HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
32. Supplementary Data. from HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
33. Supplemental Table 1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
34. Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
35. Supplemental Table 4 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
36. Data from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
37. Epidemiology of healthcare-associated SARS-CoV-2 outbreaks in Germany between March 2020 and May 2022
38. Supplemental Table 3 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
39. Impact of Storm‐Time Enhanced O2 Absorption on Disk Viewing N2 LBH Spectra: TIMED GUVI Observations.
40. Expression of the Heparan Sulfate Proteoglycan, Perlecan, during Mouse Embryogenesis and Perlecan Chondrogenic Activity in Vitro
41. Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for a future therapeutic trial exploiting LOH as a tumor vulnerability.
42. STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC).
43. Five-year prospective study of the effects of anxiety and depression in patients with coronary artery disease.
44. 80 Smarca4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association
45. 263 A2B694, an autologous logic-gated cell therapy targeting mesothelin
46. 639 BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated Tmod™ CAR T-cell therapy
47. 77 An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity
48. Placental phenotype in non‐immune hydrops fetalis with negative standard workup
49. 229 A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer
50. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.